NO20035202D0 - En adenosin A2A reseptoragonist og et antikolinergmiddel i kombinasjon forbehandling av obstruktive luftveissykdommer - Google Patents

En adenosin A2A reseptoragonist og et antikolinergmiddel i kombinasjon forbehandling av obstruktive luftveissykdommer

Info

Publication number
NO20035202D0
NO20035202D0 NO20035202A NO20035202A NO20035202D0 NO 20035202 D0 NO20035202 D0 NO 20035202D0 NO 20035202 A NO20035202 A NO 20035202A NO 20035202 A NO20035202 A NO 20035202A NO 20035202 D0 NO20035202 D0 NO 20035202D0
Authority
NO
Norway
Prior art keywords
antikolinergmiddel
adenosine
receptor agonist
respiratory diseases
obstructive respiratory
Prior art date
Application number
NO20035202A
Other languages
English (en)
Norwegian (no)
Inventor
Roisin A Armstrong
Michael Yeadon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129275A external-priority patent/GB0129275D0/en
Priority claimed from GB0210238A external-priority patent/GB0210238D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20035202D0 publication Critical patent/NO20035202D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20035202A 2001-05-25 2003-11-24 En adenosin A2A reseptoragonist og et antikolinergmiddel i kombinasjon forbehandling av obstruktive luftveissykdommer NO20035202D0 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29384201P 2001-05-25 2001-05-25
GB0129275A GB0129275D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination
GB0210238A GB0210238D0 (en) 2002-05-03 2002-05-03 Pharmaceutical composition
PCT/EP2002/005725 WO2002096462A1 (fr) 2001-05-25 2002-05-24 Combinaison d'agoniste de recepteur d'adenosine a2a et d'agent anticholinergique permettant de traiter des maladies obstructives des voies aeriennes

Publications (1)

Publication Number Publication Date
NO20035202D0 true NO20035202D0 (no) 2003-11-24

Family

ID=27256345

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035202A NO20035202D0 (no) 2001-05-25 2003-11-24 En adenosin A2A reseptoragonist og et antikolinergmiddel i kombinasjon forbehandling av obstruktive luftveissykdommer

Country Status (22)

Country Link
US (1) US20040171576A1 (fr)
EP (1) EP1395287A1 (fr)
KR (1) KR20030097901A (fr)
CN (1) CN1535161A (fr)
AP (1) AP2003002911A0 (fr)
BG (1) BG108383A (fr)
BR (1) BR0209986A (fr)
CA (1) CA2448086A1 (fr)
CO (1) CO5540324A2 (fr)
CZ (1) CZ20033126A3 (fr)
EE (1) EE200300586A (fr)
HU (1) HUP0400029A2 (fr)
IL (1) IL158774A0 (fr)
MA (1) MA27028A1 (fr)
MX (1) MXPA03010787A (fr)
NO (1) NO20035202D0 (fr)
OA (1) OA12609A (fr)
PA (1) PA8546101A1 (fr)
PL (1) PL366899A1 (fr)
SK (1) SK14302003A3 (fr)
SV (1) SV2003001055A (fr)
WO (1) WO2002096462A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
SG176313A1 (en) 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006023272A1 (fr) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation Analogues de 2-polycyclique propynyle adenosine presentant une activite agoniste de a2a
CA2576826C (fr) 2004-08-02 2014-09-30 University Of Virginia Patent Foundation Analogues de 2-propynyle adenosine comprenant des groupes 5'-ribose modifies presentant une activite agoniste a<sb>2a</sb>
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007045477A2 (fr) 2005-10-21 2007-04-26 Novartis Ag Molecules organiques
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
WO2008052734A1 (fr) 2006-10-30 2008-05-08 Novartis Ag Composés hétérocycliques en tant qu'agents anti-inflammatoires
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
WO2010088335A1 (fr) 2009-01-29 2010-08-05 Novartis Ag Benzimidazoles substitués destinés au traitement d'astrocytomes
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
CN105078978A (zh) 2009-08-17 2015-11-25 因特利凯公司 杂环化合物及其用途
WO2011020861A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composés d'oximes hétérocycliques
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
CA2828219A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composes et compositions en tant qu'inhibiteurs de trk
CA2848809A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituees en position 6 a activite tyrosine kinase
EP2793893A4 (fr) 2011-11-23 2015-07-08 Intellikine Llc Régimes de traitement améliorés utilisant des inhibiteurs de mtor
WO2013149581A1 (fr) 2012-04-03 2013-10-10 Novartis Ag Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
WO2016016822A1 (fr) 2014-07-31 2016-02-04 Novartis Ag Polythérapie
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
EP1121372B1 (fr) * 1998-10-16 2006-06-28 Pfizer Limited Derives d'adenine
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
CN1535161A (zh) 2004-10-06
CZ20033126A3 (cs) 2004-09-15
CO5540324A2 (es) 2005-07-29
HUP0400029A2 (hu) 2004-04-28
IL158774A0 (en) 2004-05-12
SV2003001055A (es) 2003-11-14
KR20030097901A (ko) 2003-12-31
SK14302003A3 (sk) 2004-08-03
OA12609A (en) 2006-06-09
MXPA03010787A (es) 2004-03-02
PL366899A1 (en) 2005-02-07
BG108383A (bg) 2004-08-31
BR0209986A (pt) 2004-04-06
MA27028A1 (fr) 2004-12-20
AP2003002911A0 (en) 2003-12-31
PA8546101A1 (es) 2003-12-10
US20040171576A1 (en) 2004-09-02
CA2448086A1 (fr) 2002-12-05
EE200300586A (et) 2004-04-15
WO2002096462A1 (fr) 2002-12-05
EP1395287A1 (fr) 2004-03-10

Similar Documents

Publication Publication Date Title
NO20035202D0 (no) En adenosin A2A reseptoragonist og et antikolinergmiddel i kombinasjon forbehandling av obstruktive luftveissykdommer
ATE293627T1 (de) Adenosin a2a rezeptor antagonisten
ATE453647T1 (de) Adenosin a2a rezeptor antagonisten
NO20052920D0 (no) 2&#39;-forgrenet nukleosider og flaviviridae mutasjon
EP1539210A4 (fr) Agonistes modifies du recepteur glp-1 et leurs procedes pharmacologiques d&#39;utilisation
DK1373470T3 (da) Hidtil ukendte substitutionsmutantreceptorer og deres anvendelse i et cellekernereceptorbaseret inducerbart genekspressionssystem
IS5696A (is) Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra
HUP0401987A3 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
IL209010A0 (en) Use of tnfalpha antibodies and another drug
IS7185A (is) Glúkagon-líkir-peptíð-1 hermar í mönnum og notkunþeirra við meðhöndlun sykursýki og skylds ástands
NO2011002I2 (no) Regadenoson og salter derav
DK1578755T3 (da) Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
ATE358130T1 (de) Bicyclische (1,2,4ö-triazol adenosin a2a rezeptor antagonisten
DK2354148T3 (da) Nukleosidanaloger og oligonukleotiderivate omfattende nukleotidanalog deraf
IL163613A0 (en) Partial and full agonists of a1 adenosine receptors
EP1444335A4 (fr) Proteines mutantes de purine nucleoside phosphorylase et l&#39;administration cellulaire de celles-ci
NO20035056D0 (no) Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes
ITMI20010957A0 (it) Derivati dell&#39;aoe-emodina e loro impiego nel trattamento di patologieneoplastiche
AU2002351175A8 (en) Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
NO20083239L (no) Anvendelse av adenosin A2A reseptor agonist for fremstilling av et topisk medikament for å akselerere helingen av et sår
DK1633355T3 (da) Benzothiazol-derivater og anvendelse deraf i behandlingen af sygdomme der er relateret til adenosin A2A-receptoren
DE60220713D1 (de) Ribofuranosyluronamid Derivate als Kristall; ein menschlicher Adenosin A2A Rezeptor Agonsit
DE60203934D1 (de) Pharmazeutische kombination von adenosine a-2a und beta-2-adrenergen rezeptoren agonisten
IS7221A (is) Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
IS7012A (is) Adenósín A2A viðtaka gerandefni og and-kólínergurmiðill í blöndu til meðhöndlunar á teppandi kokrennusjúkdómum

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application